These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 21569348)
1. Interaction of a traditional Chinese Medicine (PHY906) and CPT-11 on the inflammatory process in the tumor microenvironment. Wang E; Bussom S; Chen J; Quinn C; Bedognetti D; Lam W; Guan F; Jiang Z; Mark Y; Zhao Y; Stroncek DF; White J; Marincola FM; Cheng YC BMC Med Genomics; 2011 May; 4():38. PubMed ID: 21569348 [TBL] [Abstract][Full Text] [Related]
2. The number of intestinal bacteria is not critical for the enhancement of antitumor activity and reduction of intestinal toxicity of irinotecan by the Chinese herbal medicine PHY906 (KD018). Lam W; Jiang Z; Guan F; Hu R; Liu SH; Chu E; Cheng YC BMC Complement Altern Med; 2014 Dec; 14():490. PubMed ID: 25510341 [TBL] [Abstract][Full Text] [Related]
3. The four-herb Chinese medicine PHY906 reduces chemotherapy-induced gastrointestinal toxicity. Lam W; Bussom S; Guan F; Jiang Z; Zhang W; Gullen EA; Liu SH; Cheng YC Sci Transl Med; 2010 Aug; 2(45):45ra59. PubMed ID: 20720216 [TBL] [Abstract][Full Text] [Related]
4. WGCNA reveals key gene modules regulated by the combined treatment of colon cancer with PHY906 and CPT11. Xing S; Wang Y; Hu K; Wang F; Sun T; Li Q Biosci Rep; 2020 Sep; 40(9):. PubMed ID: 32812032 [TBL] [Abstract][Full Text] [Related]
5. PHY906(KD018), an adjuvant based on a 1800-year-old Chinese medicine, enhanced the anti-tumor activity of Sorafenib by changing the tumor microenvironment. Lam W; Jiang Z; Guan F; Huang X; Hu R; Wang J; Bussom S; Liu SH; Zhao H; Yen Y; Cheng YC Sci Rep; 2015 Mar; 5():9384. PubMed ID: 25819872 [TBL] [Abstract][Full Text] [Related]
6. A phase I study of the chinese herbal medicine PHY906 as a modulator of irinotecan-based chemotherapy in patients with advanced colorectal cancer. Kummar S; Copur MS; Rose M; Wadler S; Stephenson J; O'Rourke M; Brenckman W; Tilton R; Liu SH; Jiang Z; Su T; Cheng YC; Chu E Clin Colorectal Cancer; 2011 Jun; 10(2):85-96. PubMed ID: 21859559 [TBL] [Abstract][Full Text] [Related]
7. Identification of chemicals and their metabolites from PHY906, a Chinese medicine formulation, in the plasma of a patient treated with irinotecan and PHY906 using liquid chromatography/tandem mass spectrometry (LC/MS/MS). Zhang W; Saif MW; Dutschman GE; Li X; Lam W; Bussom S; Jiang Z; Ye M; Chu E; Cheng YC J Chromatogr A; 2010 Sep; 1217(37):5785-93. PubMed ID: 20696432 [TBL] [Abstract][Full Text] [Related]
8. A new herbal formula BP10A exerted an antitumor effect and enhanced anticancer effect of irinotecan and oxaliplatin in the colon cancer PDTX model. Kim J; Kim HY; Hong S; Shin S; Kim YA; Kim NS; Bang OS Biomed Pharmacother; 2019 Aug; 116():108987. PubMed ID: 31112870 [TBL] [Abstract][Full Text] [Related]
9. Old formula, new Rx: the journey of PHY906 as cancer adjuvant therapy. Liu SH; Cheng YC J Ethnopharmacol; 2012 Apr; 140(3):614-23. PubMed ID: 22326673 [TBL] [Abstract][Full Text] [Related]
10. Preclinical studies of the Chinese Herbal Medicine formulation PHY906 (KD018) as a potential adjunct to radiation therapy. Rockwell S; Grove TA; Liu Y; Cheng YC; Higgins SA; Booth CJ Int J Radiat Biol; 2013 Jan; 89(1):16-25. PubMed ID: 22856538 [TBL] [Abstract][Full Text] [Related]
11. Effect of combined therapy with low-dose 5-aza-2'-deoxycytidine and irinotecan on colon cancer cell line HCT-15. Ishiguro M; Iida S; Uetake H; Morita S; Makino H; Kato K; Takagi Y; Enomoto M; Sugihara K Ann Surg Oncol; 2007 May; 14(5):1752-62. PubMed ID: 17195906 [TBL] [Abstract][Full Text] [Related]
12. A Multifunctional Nanotherapy for Targeted Treatment of Colon Cancer by Simultaneously Regulating Tumor Microenvironment. Zhang Q; Zhang F; Li S; Liu R; Jin T; Dou Y; Zhou Z; Zhang J Theranostics; 2019; 9(13):3732-3753. PubMed ID: 31281510 [TBL] [Abstract][Full Text] [Related]
13. Traditional Chinese medicine Gegen Qinlian decoction ameliorates irinotecan chemotherapy-induced gut toxicity in mice. Wu Y; Wang D; Yang X; Fu C; Zou L; Zhang J Biomed Pharmacother; 2019 Jan; 109():2252-2261. PubMed ID: 30551482 [TBL] [Abstract][Full Text] [Related]
14. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice. Naka T; Sugamura K; Hylander BL; Widmer MB; Rustum YM; Repasky EA Cancer Res; 2002 Oct; 62(20):5800-6. PubMed ID: 12384541 [TBL] [Abstract][Full Text] [Related]
15. Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice. Allegrini G; Goulette FA; Darnowski JW; Calabresi P Cancer Chemother Pharmacol; 2004 Mar; 53(3):261-6. PubMed ID: 14658007 [TBL] [Abstract][Full Text] [Related]
16. Prevention of intestinal toxic effects and intensification of irinotecan's therapeutic efficacy against murine colon cancer liver metastases by oral administration of the lipopeptide JBT 3002. Shinohara H; Killion JJ; Kuniyasu H; Kumar R; Fidler IJ Clin Cancer Res; 1998 Sep; 4(9):2053-63. PubMed ID: 9748119 [TBL] [Abstract][Full Text] [Related]
17. Treatment of human colon cancer xenografts with TRA-8 anti-death receptor 5 antibody alone or in combination with CPT-11. Oliver PG; LoBuglio AF; Zinn KR; Kim H; Nan L; Zhou T; Wang W; Buchsbaum DJ Clin Cancer Res; 2008 Apr; 14(7):2180-9. PubMed ID: 18381960 [TBL] [Abstract][Full Text] [Related]
18. Research Status and Molecular Mechanism of the Traditional Chinese Medicine and Antitumor Therapy Combined Strategy Based on Tumor Microenvironment. Zhang Y; Lou Y; Wang J; Yu C; Shen W Front Immunol; 2020; 11():609705. PubMed ID: 33552068 [TBL] [Abstract][Full Text] [Related]
19. Effect and Molecular Mechanisms of Traditional Chinese Medicine on Tumor Targeting Tumor-Associated Macrophages. He J; Yin P; Xu K Drug Des Devel Ther; 2020; 14():907-919. PubMed ID: 32184560 [TBL] [Abstract][Full Text] [Related]
20. Irinotecan overcomes the resistance to 5-fluorouracil in human colon cancer xenografts by down-regulation of intratumoral thymidylate synthase. Fukushima M; Sakamoto K; Ohshimo H; Nakagawa F; Taguchi T Oncol Rep; 2010 Oct; 24(4):835-42. PubMed ID: 20811661 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]